In conclusion, our preclinical and clinical data provide a strong argument to combine inhibitors of the MAPK and the PI3K/AKT pathways to overcome resistance to cetuximab in RAS-mutated colorectal cancer. This evidence concerns the gene PIK3CA and colorectal cancer.